PODD Stock Summary and Trading Ideas (Insulet | NASDAQ:PODD)

Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, more than 600,000 insulin-dependent diabetic patients are using it worldwide.

Insulet trades on the NASDAQ stock market under the symbol PODD.

As of June 29, 2026, PODD stock price declined to $157.74 with 1,409,428 million shares trading.

PODD has a beta of -0.05, meaning it tends to be less sensitive to market movements. PODD has a correlation of 0.00 to the broad based SPY ETF.

PODD has a market cap of $11.10 billion. This is considered a Large Cap stock.

Last quarter Insulet reported $762 million in Revenue and $1.42 earnings per share. This beat revenue expectation by $32 million and exceeded earnings estimates by $.24.

In the last 3 years, PODD traded as high as $354.88 and as low as $125.82.

The top ETF exchange traded funds that PODD belongs to (by Net Assets): VTI, VOO, RSP, IVV, SPY.

PODD has underperformed the market in the last year with a return of -49.6%, while the SPY ETF gained +21.7%. In the last 3 month period, PODD fell short of the market, returning -24.2%, while SPY returned +17.2%. However, in the most recent 2 weeks PODD has outperformed the stock market by returning +6.5%, while SPY returned -1.6%.

PODD support price is $153.59 and resistance is $162.91 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PODD shares will trade within this expected range on the day.